IN172468B - - Google Patents

Info

Publication number
IN172468B
IN172468B IN421CA1991A IN172468B IN 172468 B IN172468 B IN 172468B IN 421CA1991 A IN421CA1991 A IN 421CA1991A IN 172468 B IN172468 B IN 172468B
Authority
IN
India
Prior art keywords
flupirtine
disorders
compound
treatment
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Juergen Prof Engel
Peter Dr Emig
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Priority to IN421CA1991 priority Critical patent/IN172468B/en
Priority to EP91111124A priority patent/EP0467164B1/de
Priority to DK95101189T priority patent/DK0659410T3/da
Priority to ES91111124T priority patent/ES2082887T3/es
Priority to DE4122166A priority patent/DE4122166A1/de
Priority to EP95101189A priority patent/EP0659410B1/de
Priority to AT95101189T priority patent/ATE206919T1/de
Priority to DE59109222T priority patent/DE59109222D1/de
Priority to DE59107331T priority patent/DE59107331D1/de
Priority to ES95101189T priority patent/ES2164111T3/es
Priority to AT91111124T priority patent/ATE133564T1/de
Priority to DK91111124.3T priority patent/DK0467164T3/da
Priority to MC912203A priority patent/MC2272A1/xx
Priority to SK2101-91A priority patent/SK279567B6/sk
Priority to CS912101A priority patent/CZ280879B6/cs
Priority to EG41291A priority patent/EG19814A/xx
Priority to RO147972A priority patent/RO108220B1/ro
Priority to MX9100160A priority patent/MX9100160A/es
Priority to US07/726,408 priority patent/US5162346A/en
Priority to PT98291A priority patent/PT98291B/pt
Priority to ZA915466A priority patent/ZA915466B/xx
Priority to HU912359A priority patent/HU206973B/hu
Priority to SI9111227A priority patent/SI9111227B/sl
Priority to NO91912758A priority patent/NO912758L/no
Priority to NZ238940A priority patent/NZ238940A/en
Priority to AU80403/91A priority patent/AU634073B2/en
Priority to CA002046943A priority patent/CA2046943C/en
Priority to IL9881091A priority patent/IL98810A/en
Priority to IE245191A priority patent/IE74688B1/en
Priority to SU915001150A priority patent/RU2070408C1/ru
Priority to CN91104030A priority patent/CN1070700C/zh
Priority to KR1019910011967A priority patent/KR0182811B1/ko
Priority to US07/890,730 priority patent/US5284861A/en
Priority to HRP-1227/91A priority patent/HRP920667B1/xx
Priority to LVP-92-173A priority patent/LV10048B/lv
Publication of IN172468B publication Critical patent/IN172468B/en
Priority to LTIP919A priority patent/LT3593B/lt
Priority to GR960400581T priority patent/GR3019179T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Medicines Containing Plant Substances (AREA)
IN421CA1991 1990-07-14 1991-06-04 IN172468B (sk)

Priority Applications (37)

Application Number Priority Date Filing Date Title
IN421CA1991 IN172468B (sk) 1990-07-14 1991-06-04
EP91111124A EP0467164B1 (de) 1990-07-14 1991-07-04 Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DK95101189T DK0659410T3 (da) 1990-07-14 1991-07-04 Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger
ES91111124T ES2082887T3 (es) 1990-07-14 1991-07-04 Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
DE4122166A DE4122166A1 (de) 1990-07-14 1991-07-04 Verwendung des wirkstoffs flupirtin zur bekaempfung von muskelverspannungen
EP95101189A EP0659410B1 (de) 1990-07-14 1991-07-04 Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
AT95101189T ATE206919T1 (de) 1990-07-14 1991-07-04 Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE59109222T DE59109222D1 (de) 1990-07-14 1991-07-04 Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
DE59107331T DE59107331D1 (de) 1990-07-14 1991-07-04 Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
ES95101189T ES2164111T3 (es) 1990-07-14 1991-07-04 Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
AT91111124T ATE133564T1 (de) 1990-07-14 1991-07-04 Flupirtin in kombination mit antiparkinsonika zur bekämpfung von muskelverspannungen
DK91111124.3T DK0467164T3 (da) 1990-07-14 1991-07-04 Anvendelse af det virksomme stof flupirtin i kombination med antiparkinsonika til bekæmpelse af muskelspændinger
MC912203A MC2272A1 (fr) 1990-07-14 1991-07-05 Utilisation de la substance active nommee flupirtine pour combattre des contractures musculaires
SK2101-91A SK279567B6 (sk) 1990-07-14 1991-07-08 Použitie flupirtínu alebo jeho terapeuticky zhodno
CS912101A CZ280879B6 (cs) 1990-07-14 1991-07-08 Použití účinné látky flupirtinu pro odstranení svalového přepětí
EG41291A EG19814A (en) 1990-07-14 1991-07-09 A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
RO147972A RO108220B1 (ro) 1990-07-14 1991-07-09 Preparate farmaceutice,pentru combaterea carceilor musculari si procedeu de obtinere a acestora
MX9100160A MX9100160A (es) 1990-07-14 1991-07-10 Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares
US07/726,408 US5162346A (en) 1990-07-14 1991-07-10 Pharmaceutical composition comprising flupirtine and its use to combat muscular tension
PT98291A PT98291B (pt) 1990-07-14 1991-07-11 Processo para a preparacao de composicoes farmaceuticas contendo flupirtina para combater distensoes musculares
IE245191A IE74688B1 (en) 1990-07-14 1991-07-12 Flupirtine in combination with antiparkinsonica against muscle bracing
SU915001150A RU2070408C1 (ru) 1990-07-14 1991-07-12 Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона
SI9111227A SI9111227B (sl) 1990-07-14 1991-07-12 Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic
NO91912758A NO912758L (no) 1990-07-14 1991-07-12 Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
NZ238940A NZ238940A (en) 1990-07-14 1991-07-12 Pharmaceutical compositions containing flupirtine and an antiparkinson agent; the use of flupirtine in the manufacture of a medicament to combat muscular tension
AU80403/91A AU634073B2 (en) 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
CA002046943A CA2046943C (en) 1990-07-14 1991-07-12 Process for producing an agent with the active substance flupirtine to combat muscular tension
IL9881091A IL98810A (en) 1990-07-14 1991-07-12 Pharmaceuticals containing flopirtin against disorders of muscle tension and their preparation
ZA915466A ZA915466B (en) 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
HU912359A HU206973B (en) 1990-07-14 1991-07-12 Process for producing pharmaceutical compositions comprising flupirin as active ingredient
CN91104030A CN1070700C (zh) 1990-07-14 1991-07-13 含氟吡氨酯药物的制备方法及其在治疗肌紧张中的应用
KR1019910011967A KR0182811B1 (ko) 1990-07-14 1991-07-13 근육긴장을 억제하기 위한 활성물질 플루피르틴-함유 약제 및 이의 제조방법
US07/890,730 US5284861A (en) 1990-07-14 1992-06-01 Pharmaceutical composition comprising flupirtine and its use to combat Parkinson disorders
HRP-1227/91A HRP920667B1 (en) 1990-07-14 1992-09-30 Application of fultripine active substance for preventing muscle deformation
LVP-92-173A LV10048B (en) 1990-07-14 1992-10-27 Medical agent and method for producing thereof
LTIP919A LT3593B (en) 1990-07-14 1993-09-03 Drugs and process for preparing thereof
GR960400581T GR3019179T3 (en) 1990-07-14 1996-03-05 Flupirtine in combination with antiparkinsonica against muscle bracing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (sk) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
IN172468B true IN172468B (sk) 1993-08-14

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
IN421CA1991 IN172468B (sk) 1990-07-14 1991-06-04

Country Status (30)

Country Link
US (2) US5162346A (sk)
EP (2) EP0467164B1 (sk)
KR (1) KR0182811B1 (sk)
CN (1) CN1070700C (sk)
AT (2) ATE206919T1 (sk)
AU (1) AU634073B2 (sk)
CA (1) CA2046943C (sk)
CZ (1) CZ280879B6 (sk)
DE (3) DE59109222D1 (sk)
DK (2) DK0659410T3 (sk)
EG (1) EG19814A (sk)
ES (2) ES2082887T3 (sk)
GR (1) GR3019179T3 (sk)
HR (1) HRP920667B1 (sk)
HU (1) HU206973B (sk)
IE (1) IE74688B1 (sk)
IL (1) IL98810A (sk)
IN (1) IN172468B (sk)
LT (1) LT3593B (sk)
LV (1) LV10048B (sk)
MC (1) MC2272A1 (sk)
MX (1) MX9100160A (sk)
NO (1) NO912758L (sk)
NZ (1) NZ238940A (sk)
PT (1) PT98291B (sk)
RO (1) RO108220B1 (sk)
RU (1) RU2070408C1 (sk)
SI (1) SI9111227B (sk)
SK (1) SK279567B6 (sk)
ZA (1) ZA915466B (sk)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CZ2002411A3 (cs) * 1999-08-03 2003-03-12 Awd. Pharma Gmbh & Co. Kg Farmaceutický prostředek pro léčení bolesti stejně jako prevenci chronických bolestí při degenerativních chorobách kloubů u psů a koček
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
HUT59313A (en) 1992-05-28
NO912758D0 (no) 1991-07-12
DK0467164T3 (da) 1996-03-04
MX9100160A (es) 1992-02-28
PT98291A (pt) 1992-05-29
EP0467164A3 (en) 1992-04-15
CA2046943A1 (en) 1992-01-15
ES2082887T3 (es) 1996-04-01
HRP920667B1 (en) 1998-06-30
PT98291B (pt) 1999-01-29
ATE133564T1 (de) 1996-02-15
IE74688B1 (en) 1997-07-30
LTIP919A (en) 1995-03-27
US5284861A (en) 1994-02-08
DK0659410T3 (da) 2001-12-27
DE59107331D1 (de) 1996-03-14
EP0467164A2 (de) 1992-01-22
LV10048A (lv) 1994-05-10
EP0659410B1 (de) 2001-10-17
CZ280879B6 (cs) 1996-04-17
AU634073B2 (en) 1993-02-11
SI9111227A (en) 1995-06-30
ZA915466B (en) 1992-04-29
MC2272A1 (fr) 1993-06-23
SK279567B6 (sk) 1999-01-11
RU2070408C1 (ru) 1996-12-20
EP0659410A3 (de) 1995-10-25
KR920002147A (ko) 1992-02-28
IL98810A0 (en) 1992-07-15
LT3593B (en) 1995-12-27
LV10048B (en) 1995-06-20
HU206973B (en) 1993-03-01
CA2046943C (en) 1996-03-12
ES2164111T3 (es) 2002-02-16
CS210191A3 (en) 1992-02-19
KR0182811B1 (ko) 1999-05-01
RO108220B1 (ro) 1994-03-31
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
IL98810A (en) 1996-01-19
EG19814A (en) 1996-02-29
IE912451A1 (en) 1992-01-15
HRP920667A2 (en) 1996-10-31
EP0467164B1 (de) 1996-01-31
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
CN1058716A (zh) 1992-02-19
HU912359D0 (en) 1991-12-30
SI9111227B (sl) 2000-12-31
ATE206919T1 (de) 2001-11-15
NO912758L (no) 1992-01-15
DE59109222D1 (de) 2001-11-22
AU8040391A (en) 1992-01-16
EP0659410A2 (de) 1995-06-28
DE4122166A1 (de) 1992-01-16

Similar Documents

Publication Publication Date Title
IN172468B (sk)
TW218869B (sk)
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
EP0065542A4 (en) METHOD FOR TREATING OR PROPHYLAXIS OF HEART DISORDERS.
TW249225B (sk)
ITMI913465A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fuoroetano
IN167848B (sk)
AU8656491A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
ZA9010080B (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
IL106917A0 (en) Compositions for the treatment of skin disorders
IL82295A (en) Compositions for treatment of the eyes